Xanthine oxidase-IN-19
Xanthine oxidase-IN-19 (Compound 13i) is an orally effective inhibitor of xanthine oxidase (XO), with an IC50 of 0.2 μM. Xanthine oxidase-IN-19 can significantly reduce serum uric acid levels in acute hyperuricemia rat models. Xanthine oxidase-IN-19 can be used for the study of acute hyperuricemia[1].
Product Specifications
CAS Number
3055301-22-6
Target
Xanthine Oxidase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Smiles
O=C(C1=NN=C(C2=CC3=C(N(C4CCCC4)C=C3C#N)C=C2)C=C1)O
Molecular Formula
C19H16N4O2
Molecular Weight
332.36
References & Citations
[1]Li S, et al. Design, synthesis, and evaluation of N-substituted indolyl-diazine derivatives as potent xanthine oxidase inhibitors. Bioorg Chem. 2025 Oct 9;166:109076.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740149-100 1x 100 µL
CD106 / VCAM1 (1.4C3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880009-500 1x 500 µL
MART-1 / Melan-A (M2-7C10), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details